Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $98.67, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: JNJ; Concentration risk — Customer: Takeda.
Protagonist Therapeutics is a clinical-stage biopharma with no approved products, focused on two partnered programs: Icotyde (licensed to Johnson & Johnson, NDA filed July 2025 for psoriasis) and rusfertide (Takeda collaboration, NDA filed December 2025 for polycythemia vera).... Read more
Sell if holding. At $98.67, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: JNJ; Concentration risk — Customer: Takeda. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, high confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerJNJ10-K Item 1A: 'If JNJ does not elect to continue the development of or successfully commercialize Icotyde ... our business and business prospects would be adversely affected'
- HIGHCustomerTakeda10-K Item 1A: 'if Takeda does not elect to commercialize rusfertide ... our business and business prospects would be adversely affected'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $98.67, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: JNJ; Concentration risk — Customer: Takeda. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $92.54. Score 4.6/10, high confidence.
Take-profit target: $104.86 (+6.3% upside). Prior stop was $92.54. Stop-loss: $92.54.
Concentration risk — Customer: JNJ; Concentration risk — Customer: Takeda; Analyst target reached - limited upside remaining.
Protagonist Therapeutics, Inc. trades at a P/E of N/A (forward -226.9). TrendMatrix value score: 4.0/10. Verdict: Sell.
19 analysts cover PTGX with a consensus score of 4.2/5. Average price target: $113.
What does Protagonist Therapeutics, Inc. do?Protagonist Therapeutics is a clinical-stage biopharma with no approved products, focused on two partnered programs:...
Protagonist Therapeutics is a clinical-stage biopharma with no approved products, focused on two partnered programs: Icotyde (licensed to Johnson & Johnson, NDA filed July 2025 for psoriasis) and rusfertide (Takeda collaboration, NDA filed December 2025 for polycythemia vera). Revenue is derived from collaboration milestones and royalties from JNJ and Takeda.